Changing the Paradigm of Cancer Treatment
For the past three decades, members of our team have been at the forefront of cancer immunotherapy. Today, we are a leader in engineered T cell therapy, transforming cancer treatment with what is potentially the biggest breakthrough since the introduction of combination chemotherapy more than 60 years ago.
To bring about this transformation, we're developing innovative products that harness a patient's own immune system to target and kill cancer cells. In just three years, our singular focus and strategic collaborations, including multiple Cooperative Research and Development Agreements with the National Cancer Institute, have enabled us to advance an industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates to address both hematological (blood-based) and solid cancers.
Kite by the Numbers
Clinical Trial Manufacturing Success Rate based on ZUMA-1 trial
At Kite, we've recruited the best Management Team, Board and Advisors with the vast experience in all facets of the industry to pave a new road for cancer treatment. Each person brings to Kite a special talent and unique perspective that allows us to together, successfully achieve each milestone and bring us one step closer to our unified vision.